Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Interest & Investment Income (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Interest & Investment Income for 4 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income rose 68.82% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.2 million through Dec 2025, up 32.91% year-over-year, with the annual reading at $9.2 million for FY2025, 32.91% up from the prior year.
  • Interest & Investment Income hit $2.9 million in Q4 2025 for Taysha Gene Therapies, down from $3.2 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $3.2 million in Q3 2025 to a low of $9000.0 in Q3 2022.
  • Historically, Interest & Investment Income has averaged $1.2 million across 4 years, with a median of $1.4 million in 2024.
  • Biggest five-year swings in Interest & Investment Income: surged 12222.22% in 2023 and later dropped 21.68% in 2025.
  • Year by year, Interest & Investment Income stood at $199000.0 in 2022, then surged by 865.33% to $1.9 million in 2023, then fell by 11.5% to $1.7 million in 2024, then surged by 68.82% to $2.9 million in 2025.
  • Business Quant data shows Interest & Investment Income for TSHA at $2.9 million in Q4 2025, $3.2 million in Q3 2025, and $1.9 million in Q2 2025.